In vivo performance of simvastatin-loaded electrospun spiral-wound polycaprolactone scaffolds in reconstruction of cranial bone defects in the rat model

Journal of Biomedical Materials Research - Part A

Volumn 90, Issue 4, 2009, Pages 1137-1151

  Pişkin, Erhan ^a   Işoǧlu, I Alper ^a   Bölgen, Nimet ^a   Vargel, Ibrahim ^b   Griffiths, Sarah ^c   Çavuşoǧlu, Tarik ^b   Korkusuz, Petek ^a   Güzel, Elif ^a   Cartmell, Sarah ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c KEELE UNIVERSITY   (United Kingdom)

Author keywords

Animal model; Biodegradable scaffolds; Bone reconstruction; Cranial defects; Electrospinning; Poly( caprolactone); Simvastatin; Spiral wounding

Indexed keywords

ANIMAL MODEL; BIODEGRADABLE SCAFFOLDS; BONE RECONSTRUCTION; CRANIAL DEFECTS; SIMVASTATIN; SPIRAL-WOUNDING;

ANIMALS; BONE; COMPUTERIZED TOMOGRAPHY; DEFECTS; ELECTROSPINNING; POLYCAPROLACTONE; REPAIR; THREE DIMENSIONAL; TISSUE ENGINEERING; TOMOGRAPHY;

SCAFFOLDS;

POLYCAPROLACTONE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MINERALIZATION; BONE REGENERATION; BONE REMODELING; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; NONHUMAN; RAT; SKULL DEFECT; TISSUE ENGINEERING; X RAY;

ANIMALS; BONE REGENERATION; CALCIFICATION, PHYSIOLOGIC; OSSEOINTEGRATION; POLYESTERS; RATS; SIMVASTATIN; SKULL; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68249147417     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32157     Document Type: Article

References (71)

1. Damien CJ, Parsons JR. Bone graft and bone graft substitutes: A review of current technology and applications. J Appl Biomater 1991;2:187-208.
2. Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920-926.
3. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998;16:247-252.
4. Tuzlakoǧlu K, Bölgen N, Salgado AJ, Gomes ME, Piskin E, Reis RL. Nano- and micro-fiber combined scaffolds: A new architecture for bone tissue engineering. J Mater Sci Mater Med 2005;16:1099-1104.
5. Mistry AS, Mikos AG. Tissue engineering strategies for bone regeneration. Adv Biochem Eng Biotechnol 2005;94:1-22.
6. Alsberg E, Hill EE, Mooney DJ. Craniofacial tissue engineering. Crit Rev Oral Biol Med 2001;12:64-75.
7. Ma PX, Choi JW. Biodegradable polymer scaffolds with well-defined interconnected spherical pore network. Tissue Eng 2001;7:23-33.
8. Bölgen N, Plieva F, Galaev IY, Mattiasson B, Piskin E. "Cryogelation" for preparation of novel biodegradable tissue engineering scaffolds. J Biomater Sci Polym Ed 2007;18:1165-1169.
9. Sharma B, Elisseeff JH. Engineering structurally organized cartilage and bone tissues. Ann Biomed Eng 2004;32:148-159.
10. Caplan AI. Tissue engineering designs for the future: New logics, old molecules. Tissue Eng 2000;6:1-8.
11. Liu X, Ma PX. Polymeric scaffolds for bone tissue engineering. Ann Biomed Eng 2004;32:477-486.
12. Hou QP, Grijpma DW, Feijen J. Porous polymeric structures for tissue engineering prepared by a coagulation, compression molding and salt leaching technique. Biomaterials 2003;24:1937-1947.
13. Huang ZM, Zhang YZ, Kotaki M, Ramakrishna S. A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Compos Sci Technol 2003;63:2223-2253.
14. Lannutti J, Reneker D, Ma T, Tomasko D, Farson D. Electrospinning for tissue engineering scaffolds. Mater Sci Eng C 2007;27:504-509.
15. Smith LA, Ma PX. Nano-fibrous scaffolds for tissue engineering. Colloids Surf B Biointerfaces 2004;39:125-131.
16. Pişkin E, Bölgen N, Eǧri S, İşoǧlu İA. Electrospun matrices made of poly(α-hydroxy acids) for medical use. Nanomedicine 2007;2:441-457.
17. Bölgen N, Vargel İ, Korkusuz P, Menceloǧlu YZ, Pişkin E. In vivo performance of antibiotic embedded electrospun PCL membranes for prevention of abdominal adhesions. J Biomedical Mater Res B Appl Biomater 2007;81:530-543.
18. Fambri L, Migliaresi C, Kesenci K, Pişkin E. Biodegradable polymers, In: Barbucci R, editor. Integrated Biomaterials Science. New York: Kluwer; 2002. p 119-187.
19. Pişkin E. Biodegradable polymers in medicine. In: Scott G, editor. Degradable Polymers: Principles and Applications. Dordrecht: Kluwer; 2002. p 321-377.
20. Pitt CG. Poly (ε-caprolactone) and its copolymers. In: Chasin M, Langer R, editors. Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker; 1990. p 71-120.
21. Hutmacher DW, Schantz T, Zein I, Ng KW, Teoh SH, Tan KC. Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. J Biomed Mater Res 2001;55:203-216.
22. Ekholm M, Hietanen J, Lindqvist C, Rautavuori J, Santavirta S, Suuronen R. Histological study of tissue reactions to epsilon-caprolactone-lactide copolymer in paste form. Biomaterials 1999;20:1257-1262.
23. Ng KW, Hutmacher DW, Schantz JT, Ng CS, Too HP, Lim TC, Phan TT, Teoh SH. Evaluation of ultra-thin poly(epsilon-caprolactone) films for tissue-engineered skin. Tissue Eng 2001;7:441-455.
24. Li W, Laurencin C, Caterson E, Tuan R, Ko F. Electospun nanofibrous structure: A novel scaffold for tissue engineering. J Biomed Mater Res 2002;60:613-621.
25. Bölgen N, Menceloǧlu YZ, Açatay K, Vargel İ, Pişkin E. In vitro and in vivo degradation of non-woven materials made of poly(e-caprolactone) nanofibers prepared by electrospinning at different conditions. J Biomater Sci Polym Ed 2005;16:1537-1555.
26. Pratt AB, Weber FE, Schmoekel HG, Müller R, Hubbell JA. Synthetic extracellular matrices for in situ tissue engineering. Biotechnol Bioeng 2004;86:27-36.
27. Kim HW, Knowles JC, Kim HE. Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery. Biomaterials 2004;25:1279-1287.
28. Hu JJ, Jin D, Quan DP, Zong SZ, Chen JH, Wei KH, Zhao J, Pei GX. Bone defect repair with a new tissue-engineered bone carrying bone morphogenetic protein in rabbits. Di Yi Jun Yi Da Xue Xue Bao 2005;25:1369-1374.
29. Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2000;21:2521-2527.
30. Whang K, Goldstick TK, Healy KE. A biodegradable polymer scaffold for delivery of osteotropic factors. Biomaterials 2000;21:2545-2551.
31. Babensee JE, McIntire LV, Mikos AG. Growth factor delivery for tissue engineering. Pharm Res 2000;17:497-504.
32. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;271:688-692.
33. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 2001;7:715-736.
34. Staal A, Frith JC, French MH, Swartz J, Güngör T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003;18:88-96.
35. Hu H, Sung A, Zhao G. Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun 2006;339:59-64.
36. Yee AJ, Bae HW, Friess D. The use of simvastatin in rabbit posterolateral lumbar intertransverse process spine fusion. Spine J 2006;6:391-396.
37. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. J Am Cardiol 2003;91:11-17.
38. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. J Am Med Assoc 2004;291:2821-2827.
39. Furberg CD. Natural statins and stroke risk. Circulation 1999;99:185-188.
40. Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 2001;32:1112-1115.
41. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-968.
42. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ. Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000;153:181-189.
43. Lane NE, Kelman A. A review of anabolic therapies for osteoporosis. Arthr Res Ther 2003;5:214-222.
44. Rogers MJ. Statins: Lower lipids and better bones? Nat Med 2000;6:21-23.
45. Cauley J, Jackson R, Pettinger M, Lacroix A, Bauer D, Chen Z, Daugherty S, Hsia J, Lewis C, McGowan J, McNeeley S, Passaro M. Statin use and bone mineral density (BMD) in older women. J Bone Min Res 2000;15:155.
46. Garrett IR, Mundy G. The role of statins as potential targets for bone formation. Arthr Res 2002;4:237-240.
47. Vogel G. Cholesterol-lowering drugs may boost bones. Science 1999;286:1825-1826.
48. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355:2218-2219.
49. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HAP. Use of statins and fracture: Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146-152.
50. Toh S, Hernandez-Diaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007;16:627-640.
51. Wong RWK, Rabie ABM. Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg 2003;41:244-248.
52. Wong RWK, Rabie ABM. Early healing pattern of statin-induced osteogenesis. Br J Oral Maxillofac Surg 2005;43:46-50.
53. Maritz F, Conradie M, Hulley P, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001;21:1565-1566.
54. Ural E, Kesenci K, Fambri L, Migliaresi C, Pişkin E. Poly(D,L-lactide/ε-caprolactone)/hydroxyapatite composites as bone filler: Preparation and characterization. Biomaterials 2000;21:2147-2154.
55. İšoǧlu, İA. Scaffolds based on electrospun poly(ε-caprolactone) membranes for bone tissue engineering. PhD Thesis. Hacettepe University, Ankara, Turkey, 2007.
56. Burdicka JA, Frankelb D, Dernellb WS, Ansetha KS. An initial investigation of photocurable three-dimensional lactic acid based scaffolds in a critical-sized cranial defect. Biomaterials 2003;24:1613-1620.
57. Jaecques SVN, Van Oosterwyck H, Muraru L, Van Cleynenbreugel T, De Smet E, Wevers M, Naert I, Vander Sloten J. Individualised, micro CT-based finite element modelling as a tool for biomechanical analysis related to tissue engineering of bone. Biomaterials 2004;25:1682-1696.
58. Schantz JT, Teoh SH, Lim TC, Lim TC, Endres M, Lam CX, Hutmacher DW. Repair of calvarial defects with customized tissue-engineered bone grafts. I. Evaluation of osteogenesis in a three-dimensional culture system. Tissue Eng 2003;9:S113-S126.
59. Schantz JT, Hutmacher DW, Lam CXF, Bringmann M, Wong KM, Lim TC, Chou N, Re G, Teoh SH. Repair of calvarial defects with customised tissue-engineered bone grafts. II. Evaluation of cellular efficiency and efficacy in vivo. Tissue Eng 2003;9:S127-S139.
60. Meinel L, Karageorgiou V, Hofmann S, Fajardo R, Snyder B, Li C, Zichner L, Langer R, Vunjak-Novakovic G, Kaplan DL. J Biomed Mater Res Part A 2004;71:25-34.
61. Tuan HS, Hutmacher DW. Application of micro CT and computation modeling in bone tissue engineering. Comput Aid Des 2005;37:1151-1161.
62. Li S, McCarthy S. Further investigations on the hydrolytic degradation of poly(DL-lactide). Biomaterials 1999;20:35-44.
63. Lu L, Garcia CA, Mikos AG. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res 1999;46:236-244.
64. Grizzi I, Garreau H, Li S, Vert M. Hydrolytic degradation of devices based on poly(DL-lactide) size dependence. Biomaterials 1995;16:305-311.
65. Gan Z, Yu D, Zhong Z, Liang Q, Jing X. Enzymatric degradation of poly(caprolactone)/poly(DL-lactide) blends in phosphate buffer solution. Polymer 1999;40:2859-2862.
66. Pitt CG, Marks TA, Schindler A. Biodegradable drug delivery systems based on aliphatic polyesters: Application to contraceptives and narcotic antagonists. NIDA Res Monogr 1981;28:232-253.
67. Li SM, Liu LJ, Garreau H, Vert M. Lipase-catalysed biodegradation of poly(ε-caprolactone) blended with various polylactide-based polymers. Biomacromolecules 2003;4:373-377.
68. Woodward SC, Brewer PS, Moatamed F, Schindler A, Pitt CG. The intracellular degradation of poly(ε-caprolactone). J Biomed Mater Res 1985;19:437-444.
69. Matlaga BF, Salthouse TN. Ultrastructural observations of cells at the interface of a biodegradable polymer: Polyglactin 910. J Biomed Mater Res 1983;17:185-197.
70. http://www.nibib1.nih.gov/.
71. The internet drug index.www.rxlist.com.